Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy for metastatic renal-cell carcinoma

  • Free Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The treatment of metastatic renal-cell carcinoma remains a major challenge. Immunotherapy is a new approach to the treatment of advanced cancer and might offer a window of hope to patients with renal-cell carcinoma. The enthusiasm for this form of cancer therapy is mainly due to the recent advances achieved in immunology and molecular biology. This report reviews our experience with immunotherapy for renal-cell carcinoma. Although it is yet experimental, adoptive immunotherapy and combined cytokine administration appears to be a promising therapeutic modality for a selected group of patients with advanced renal-cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E, Boring CC, Squires TS (1990) Cancer Stat 40:9

    Google Scholar 

  2. deKernion JB, Belldegrun A (1991) Renal tumors. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds) Campbell's urology, 6th edn. WB Saunders, Philadelphia (in press)

    Google Scholar 

  3. Belldegrun A, Rosenberg SA (1990) Adoptive immunotherapy for urologic tumors. In: Lepor H, Ratliff TL (eds) Urologic oncology. Martinus Nijhoff, Boston, pp 213–266

    Google Scholar 

  4. Brunda MJ, Bellantoni D, Sulich V (1987) In vivo antitumor activity of combinations of interferon-a and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365

    Google Scholar 

  5. Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810

    Google Scholar 

  6. Bukowski RM, Murthy S, Sergi J, Budd T, McKeever S, Medendorp SV, Tubbs R, Gibson V, Finke J (1990) Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha2a: clinical effects. J Biol Response Mod 9:538

    Google Scholar 

  7. Lee KH, Taplaz M, Rothberg JM, Murray JL, Papadopoulus N, Plager C, Benjamin R, Levitt D, Gutterman J (1989) Concomitant administration of recombinant human interleukin-2 and recombinant interferon-alpha2a in cancer patients: a phase I study. J Clin Oncol 7:1726

    Google Scholar 

  8. Rosenberg SA, Lotze MT, Yang JC, Linehan M, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863

    Google Scholar 

  9. Rosenberg SA, DeVita VT, Hellman S (1986) Adoptive immunotherapy of cancer using lymphokine-activated killer cells and recombinant interleukin-2. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. JB Lippincott, New York, p 55

    Google Scholar 

  10. Rosenberg SA, DeVita VT, Hellman S (1988) Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine-activated killer cells. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. JB Lippincott, New York, p 217

    Google Scholar 

  11. Belldegrun A, Uppenkamp I, Rosenberg SA (1988) Antitumor reactivity of human lymphokine-activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer. J Urol 139:150

    Google Scholar 

  12. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485

    CAS  PubMed  Google Scholar 

  13. Fisher RI, Coltman CA Jr, Doroshow JH et al. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann Intern Med 108:518

    Google Scholar 

  14. Parkinson DR (1990) Interleukin-2: further progress through greater understanding. J Natl Cancer Inst 82:1374

    Google Scholar 

  15. Belldegrun A, Webb DE, Austin HA et al. (1987) Effects of interleukin-2 in renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106:817

    Google Scholar 

  16. Belldegrun A, Webb DE, Austin HA et al. (1989) Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect to pretherapy nephrectomy. J Urol 141:499

    Google Scholar 

  17. Itoh K, Tilden AB, Balch CM (1986) Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46:3011–3017

    Google Scholar 

  18. Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune response against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989–995

    Google Scholar 

  19. Whiteside TL, Miescher S, Hurlimann J, Moretta L, Fliedner V von (1986) Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 37:803–811

    Google Scholar 

  20. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with infiltrating lymphocytes. Science 233:1318–1321

    Google Scholar 

  21. Alexander RB, Rosenberg SA (1990) Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 145:1615–1620

    Google Scholar 

  22. Fisher B, Packard BS, Read EF et al. (1989) Tumor localization of adoptively transferred indium III-labeled tumor-infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250–261

    Google Scholar 

  23. Griffith KO, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold PM, Packard BS, Yu MY, Rosenberg SA (1989) In vivo distribution of adoptively transferred indium III-labeled tumor-infiltrating lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81:1709–1717

    Google Scholar 

  24. Rosenberg SA, Packard BS, Aebersold PM et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676–1680

    Google Scholar 

  25. Belldegrun A, Muul LM, Rosenberg AR (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res 48:206–214

    Google Scholar 

  26. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA (1989) Human tumor-infiltrating lymphocytes: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142:4520–4526

    Google Scholar 

  27. Belldegrun A, Koo AS, Bochner B, Figlin R, deKernion JB (1990) Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur Urol 18 [Suppl 2]:42–45

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery/Division of Urology, UCLA School of Medicine, CHS 66-138, 10833 Le Conte Avenue, 90024-1738, Los Angeles, CA, USA

    A. Belldegrun & J. deKernion

  2. Department of Medicine/Division of Hematology Oncology, UCLA School of Medicine, CHS 66-138, 10833 Le Conte Avenue, 90024-1738, Los Angeles, CA, USA

    R. Figlin

  3. Wayne State University School of Medicine, 48201, Detroit, MI, USA

    G. Haas

Authors
  1. A. Belldegrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Figlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. deKernion
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belldegrun, A., Figlin, R., Haas, G. et al. Immunotherapy for metastatic renal-cell carcinoma. World J Urol 9, 157–159 (1991). https://doi.org/10.1007/BF00202513

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00202513

Keywords

Search

Navigation